Rachel Rabinovitch1, Kathryn Winter2, Robert Kuske3, John Bolton4, Doug Arthur5, Troy Scroggins6, Frank Vicini7, Beryl McCormick8, Julia White9. 1. Department of Radiation Oncology, University of Colorado Hospital, Aurora, CO. Electronic address: rachel.rabinovitch@ucdenver.edu. 2. Department of Statistics, Radiation Therapy Oncology Group, Philadelphia, PA. 3. Department of Radiation Oncology, AZ Oncology Services, Scottsdale, AZ; Radiation Oncology, Arizona Breast Cancer Specialists, Scottsdale, AZ. 4. Department of Surgery, Ochsner Clinic, New Orleans, LA. 5. Department of Radiation Oncology, Medical College of Virginia, Richmond, VA. 6. Department of Radiation Oncology, Ochsner Baptist Medical Center, New Orleans, LA. 7. Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI; Radiation Oncology, Michigan HealthCare Professionals/21st Century Oncology, Farmington Hills, MI. 8. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY. 9. Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI; Department of Radiation Oncology, Ohio State University Medical Center, Columbus, OH.
Abstract
PURPOSE: Radiation Therapy Oncology Group (RTOG) 95-17, a Phase II trial to evaluate multicatheter brachytherapy (mCathBrachy) as the sole method of radiation therapy for Stage I-II breast cancer (BrCa), was the first cooperative group trial in North America to evaluate accelerated partial breast irradiation (APBI) and include patient-reported outcomes (PROs). This report presents the year-5 toxicity and cosmesis data. METHODS AND MATERIALS: After lumpectomy and axillary dissection for invasive BrCa (tumor size <3cm with zero to three positive lymph nodes), 100 patients (pts), 98 evaluable, were treated (txed) with mCathBrachy from 1997 to 2000 with 34Gy administered twice daily in 10 high-dose-rate fractions or 45Gy in 3.5-6 days as a low-dose-rate implant to 1-2cm beyond the lumpectomy bed. The PROs and physician-reported outcomes of toxicity, cosmesis, and tx satisfaction at year-5 are reported here, defined as data submitted 54-78 months after tx. RESULTS: Grade (G) 1-2 skin toxicity developed in 78% of the pts and G3 in 13% (no G4). The tx effects included skin dimpling/indentation (37%), fibrosis (45%), telangiectasias (45%), skin catheter marks (54%), and symptomatic fat necrosis (15%). Breast asymmetry was reported in 73%. Rates of excellent-to-good cosmesis were similar between PROs (66%) and radiation oncologists (68%). The PROs of tx satisfaction at year-5 was 75%. CONCLUSIONS: RTOG 95-17 documents the year-5 skin toxicity and tx effects of mCathBrachy APBI, which are associated with PROs of good-to-excellent cosmesis and high tx satisfaction. This emphasizes the importance of PROs when assessing BrCa tx. National Surgical Adjuvant Breast and Bowel Project B39/RTOG 0413 will allow for definitive comparisons between APBI and whole breast radiation therapy.
PURPOSE: Radiation Therapy Oncology Group (RTOG) 95-17, a Phase II trial to evaluate multicatheter brachytherapy (mCathBrachy) as the sole method of radiation therapy for Stage I-II breast cancer (BrCa), was the first cooperative group trial in North America to evaluate accelerated partial breast irradiation (APBI) and include patient-reported outcomes (PROs). This report presents the year-5 toxicity and cosmesis data. METHODS AND MATERIALS: After lumpectomy and axillary dissection for invasive BrCa (tumor size <3cm with zero to three positive lymph nodes), 100 patients (pts), 98 evaluable, were treated (txed) with mCathBrachy from 1997 to 2000 with 34Gy administered twice daily in 10 high-dose-rate fractions or 45Gy in 3.5-6 days as a low-dose-rate implant to 1-2cm beyond the lumpectomy bed. The PROs and physician-reported outcomes of toxicity, cosmesis, and tx satisfaction at year-5 are reported here, defined as data submitted 54-78 months after tx. RESULTS:Grade (G) 1-2skin toxicity developed in 78% of the pts and G3 in 13% (no G4). The tx effects included skin dimpling/indentation (37%), fibrosis (45%), telangiectasias (45%), skin catheter marks (54%), and symptomatic fat necrosis (15%). Breast asymmetry was reported in 73%. Rates of excellent-to-good cosmesis were similar between PROs (66%) and radiation oncologists (68%). The PROs of tx satisfaction at year-5 was 75%. CONCLUSIONS: RTOG 95-17 documents the year-5 skin toxicity and tx effects of mCathBrachy APBI, which are associated with PROs of good-to-excellent cosmesis and high tx satisfaction. This emphasizes the importance of PROs when assessing BrCa tx. National Surgical Adjuvant Breast and Bowel Project B39/RTOG 0413 will allow for definitive comparisons between APBI and whole breast radiation therapy.
Authors: Jayant S Vaidya; David J Joseph; Jeffrey S Tobias; Max Bulsara; Frederik Wenz; Christobel Saunders; Michael Alvarado; Henrik L Flyger; Samuele Massarut; Wolfgang Eiermann; Mohammed Keshtgar; John Dewar; Uta Kraus-Tiefenbacher; Marc Sütterlin; Laura Esserman; Helle M R Holtveg; Mario Roncadin; Steffi Pigorsch; Marinos Metaxas; Mary Falzon; April Matthews; Tammy Corica; Norman R Williams; Michael Baum Journal: Lancet Date: 2010-07-10 Impact factor: 79.321
Authors: D E Wazer; D Lowther; T Boyle; K Ulin; A Neuschatz; R Ruthazer; T A DiPetrillo Journal: Int J Radiat Oncol Biol Phys Date: 2001-05-01 Impact factor: 7.038
Authors: Robert R Kuske; Kathryn Winter; Douglas W Arthur; John Bolton; Rachel Rabinovitch; Julia White; William Hanson; R M Wilenzick Journal: Int J Radiat Oncol Biol Phys Date: 2006-02-28 Impact factor: 7.038
Authors: Timothy J Whelan; Jean-Philippe Pignol; Mark N Levine; Jim A Julian; Robert MacKenzie; Sameer Parpia; Wendy Shelley; Laval Grimard; Julie Bowen; Himu Lukka; Francisco Perera; Anthony Fyles; Ken Schneider; Sunil Gulavita; Carolyn Freeman Journal: N Engl J Med Date: 2010-02-11 Impact factor: 91.245
Authors: Christine E Hill-Kayser; Carolyn Vachani; Margaret K Hampshire; Gloria A Di Lullo; James M Metz Journal: Int J Radiat Oncol Biol Phys Date: 2011-12-02 Impact factor: 7.038
Authors: Csaba Polgár; Tibor Major; János Fodor; Zoltán Sulyok; András Somogyi; Katalin Lövey; György Németh; Miklós Kásler Journal: Radiother Oncol Date: 2010-02-22 Impact factor: 6.280
Authors: David E Wazer; Seth Kaufman; Laurie Cuttino; Thomas DiPetrillo; Douglas W Arthur Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-24 Impact factor: 7.038
Authors: R Orecchia; M Ciocca; R Lazzari; C Garibaldi; M C Leonardi; A Luini; M Intra; G Gatti; P Veronesi; J I Petit; U Veronesi Journal: Breast Date: 2003-12 Impact factor: 4.380
Authors: Geoffrey S Ibbott; W F Hanson; Elizabeth O'Meara; Robert R Kuske; Douglas Arthur; Rachel Rabinovitch; Julia White; Raymond M Wilenzick; Irene Harris; Ramesh C Tailor Journal: Int J Radiat Oncol Biol Phys Date: 2007-12-01 Impact factor: 7.038
Authors: Frank Vicini; Kathryn Winter; John Wong; Helen Pass; Rachel Rabinovitch; Susan Chafe; Douglas Arthur; Ivy Petersen; Julia White; Beryl McCormick Journal: Int J Radiat Oncol Biol Phys Date: 2009-11-10 Impact factor: 7.038
Authors: Kevin E Casey; Paola Alvarez; Stephen F Kry; Rebecca M Howell; Ann Lawyer; David Followill Journal: Med Phys Date: 2013-11 Impact factor: 4.071
Authors: Julia White; Kathryn Winter; Robert R Kuske; John S Bolton; Douglas W Arthur; Troy Scroggins; Rachel A Rabinovitch; Tracy Kelly; Leonard M Toonkel; Frank A Vicini; Beryl McCormick Journal: Int J Radiat Oncol Biol Phys Date: 2016-04-02 Impact factor: 7.038
Authors: Rachel Rabinovitch; Jennifer Moughan; Frank Vicini; Helen Pass; John Wong; Susan Chafe; Ivy Petersen; Douglas W Arthur; Julia White Journal: Int J Radiat Oncol Biol Phys Date: 2016-09-03 Impact factor: 7.038
Authors: Nitesh N Paryani; Laura Vallow; Wilza Magalhaes; Michael G Heckman; Siyong Kim; Ashley Smith; Nancy N Diehl; Sarah McLaughlin Journal: J Contemp Brachytherapy Date: 2015-03-05
Authors: Tobias Forster; Clara Victoria Katharina Köhler; Jürgen Debus; Juliane Hörner-Rieber Journal: Breast Care (Basel) Date: 2020-02-21 Impact factor: 2.860